Does the media favor OGN or AMPH?

In the previous week, Organon & Co. had 3 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for Organon & Co. and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat Organon & Co.'s score of 0.82 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMPH or GPCR?

In the previous week, Structure Therapeutics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Structure Therapeutics and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat Structure Therapeutics' score of 1.32 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MBX or AMPH?

In the previous week, MBX Biosciences had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for MBX Biosciences and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat MBX Biosciences' score of 1.01 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TARS or AMPH?

In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 3 mentions for Amphastar Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.63 beat Amphastar Pharmaceuticals' score of 1.32 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amphastar Pharmaceuticals (AMPH) Competitors

$22.01 +0.13 (+0.59%)

As of 08/28/2026 04:00 PM Eastern

Compare

AMPH vs. OGN, GPCR, MBX, TARS, and ARQT

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? Amphastar Pharmaceuticals's main competitors and comparable companies include Organon & Co. (OGN), Structure Therapeutics (GPCR), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Organon & Co. has higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.88
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.02

Organon & Co. presently has a consensus price target of $11.40, suggesting a potential downside of 17.21%. Amphastar Pharmaceuticals has a consensus price target of $22.50, suggesting a potential upside of 2.23%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Organon & Co. had 3 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for Organon & Co. and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat Organon & Co.'s score of 0.82 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amphastar Pharmaceuticals beats Organon & Co. on 8 of the 15 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Amphastar Pharmaceuticals currently has a consensus target price of $22.50, suggesting a potential upside of 2.23%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Structure Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Structure Therapeutics	N/A	-25.56%	-24.31%

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.02
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Amphastar Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market.

In the previous week, Structure Therapeutics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Structure Therapeutics and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat Structure Therapeutics' score of 1.32 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

MBX Biosciences has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, MBX Biosciences had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for MBX Biosciences and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat MBX Biosciences' score of 1.01 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences currently has a consensus price target of $77.00, indicating a potential upside of 22.22%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential upside of 2.23%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.02

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to MBX Biosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Amphastar Pharmaceuticals beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Amphastar Pharmaceuticals has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.02

Tarsus Pharmaceuticals currently has a consensus price target of $90.50, indicating a potential upside of 26.11%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential upside of 2.23%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 3 mentions for Amphastar Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.63 beat Amphastar Pharmaceuticals' score of 1.32 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.44	-$16.14M	$0.21	113.24
Amphastar Pharmaceuticals	$719.89M	1.30	$98.09M	$1.69	13.02

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Arcutis Biotherapeutics presently has a consensus target price of $35.57, suggesting a potential upside of 49.59%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential upside of 2.23%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Arcutis Biotherapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 12 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.32 beat Arcutis Biotherapeutics' score of 1.15 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics and Amphastar Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$936.26M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	13.02	787.65	273.16	25.45
Price / Sales	1.30	792.41	592.59	73.08
Price / Cash	5.17	91.95	76.74	53.00
Price / Book	1.22	11.97	12.98	6.14
Net Income	$98.09M	$2.83B	$3.48B	$348.86M
7 Day Performance	1.90%	0.39%	0.13%	-0.80%
1 Month Performance	8.00%	5.34%	7.08%	4.13%
1 Year Performance	-28.12%	6.05%	24.67%	15.17%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	2.0472 of 5 stars	$22.01 +0.6%	$22.50 +2.2%	-28.1%	$936.26M	$719.89M	13.02	1,976	Positive News
OGN Organon & Co.	1.8365 of 5 stars	$13.76 +0.0%	$11.40 -17.1%	+46.6%	$3.61B	$6.22B	17.86	10,000	News Coverage
GPCR Structure Therapeutics	2.2028 of 5 stars	$49.92 +1.9%	$110.91 +122.2%	+145.4%	$3.48B	N/A	N/A	136	Positive News
MBX MBX Biosciences	2.517 of 5 stars	$68.62 +3.4%	$77.00 +12.2%	+317.5%	$3.30B	N/A	N/A	N/A	News Coverage
TARS Tarsus Pharmaceuticals	3.7513 of 5 stars	$71.45 -1.9%	$90.50 +26.7%	+22.5%	$3.14B	$451.36M	N/A	50	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. OGN, GPCR, MBX, TARS, and ARQT

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Summary

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. OGN, GPCR, MBX, TARS, and ARQT

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Which has preferable earnings and valuation, OGN or AMPH?

Do analysts prefer OGN or AMPH?

Does the media favor OGN or AMPH?

Which has more risk and volatility, OGN or AMPH?

Is OGN or AMPH more profitable?

Do insiders and institutionals hold more shares of OGN or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Do analysts recommend AMPH or GPCR?

Is AMPH or GPCR more profitable?

Do insiders & institutionals hold more shares of AMPH or GPCR?

Which has stronger earnings & valuation, AMPH or GPCR?

Which has more volatility & risk, AMPH or GPCR?

Does the media prefer AMPH or GPCR?

Summary

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

Which has more volatility and risk, MBX or AMPH?

Does the media refer more to MBX or AMPH?

Do analysts recommend MBX or AMPH?

Which has preferable valuation & earnings, MBX or AMPH?

Do insiders and institutionals have more ownership in MBX or AMPH?

Is MBX or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Which has more volatility and risk, TARS or AMPH?

Is TARS or AMPH more profitable?

Which has preferable earnings & valuation, TARS or AMPH?

Do analysts rate TARS or AMPH?

Do insiders & institutionals have more ownership in TARS or AMPH?

Does the media refer more to TARS or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Do insiders and institutionals believe in ARQT or AMPH?

Which has better valuation and earnings, ARQT or AMPH?

Is ARQT or AMPH more profitable?

Do analysts rate ARQT or AMPH?

Which has more volatility & risk, ARQT or AMPH?

Does the media refer more to ARQT or AMPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools